Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes